Go back

Eli Lilly joins Stevenage Bioscience Catalyst

Pharmaceutical company Eli Lilly is to have a presence at Stevenage Bioscience Catalyst and has sponsored the catalyst’s neurodegenerative disease challenge.

A spokeswoman from Eli Lilly says that the firm expects to have a “regular presence” at the Stevenage Bioscience Catalyst, the 10,000-square-metre hub that aims to generate innovation by fostering open collaboration between biotech and life science companies. The drug company has rented a desk in the hub’s office space, which is designed to encourage interaction between tenant companies. 

The company has also announced that it is to sponsor the catalyst’s open innovation challenge in neurodegenerative disease, which launched in May 2014. The amount underlying the sponsorship has not been disclosed, but Eli Lilly will be represented on the expert panel that will review submissions. The winning applications are expected in early 2015. 

This article is only available to Research Professional News subscribers or Pivot-RP users.

If you are a Research Professional News subscriber you can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.